Blinatumomab Warning and Precautions

The drug Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 and CD3. This medicine is sold under the brand name Blincyto. Healthcare professionals recommend using this medicine for treating patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Blincyto is supplied in a single-dose vial for intravenous infusion in […]

Blincyto Treatment for Acute Lymphoblastic Leukemia

Introduction: Acute lymphoblastic leukemia (ALL) is a sort of blood cancer. ALL can also be addressed by certain other names such as “acute lymphocytic leukemia” and “acute lymphoid leukemia.” ALL is most commonly developed leukemia in children. Advances in the treatment of ALL have resulted increased remission rates. The number of patients who have gone […]